Taysha Gene Therapies Inc. (TSHA): Price and Financial Metrics


Taysha Gene Therapies Inc. (TSHA): $1.64

0.10 (+6.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TSHA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TSHA Stock Price Chart Interactive Chart >

Price chart for TSHA

TSHA Price/Volume Stats

Current price $1.64 52-week high $8.93
Prev. close $1.54 52-week low $1.35
Day low $1.52 Volume 780,696
Day high $1.71 Avg. volume 469,998
50-day MA $2.10 Dividend yield N/A
200-day MA $2.95 Market Cap 102.40M

Taysha Gene Therapies Inc. (TSHA) Company Bio


Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.


TSHA Latest News Stream


Event/Time News Detail
Loading, please wait...

TSHA Latest Social Stream


Loading social stream, please wait...

View Full TSHA Social Stream

Latest TSHA News From Around the Web

Below are the latest news stories about TAYSHA GENE THERAPIES INC that investors may wish to consider to help them evaluate TSHA as an investment opportunity.

Biotech signals potential pullback from 200-job Durham plant

State officials have terminated an incentive agreement for a Texas-based biotech that had planned to invest $75 million in a manufacturing facility in Durham. The state's Economic Investment Committee, part of the North Carolina Department of Commerce, voted unanimously Tuesday to terminate a package awarded to Taysha Gene Therapies (Nasdaq: TSHA) in late 2020. The vote was in response to a letter the department received from the company requesting withdrawal from the state's Job Development Investment Grant program.

Yahoo | January 24, 2023

How did Taysha Gene Therapies Inc. (TSHA) fare last session?

In Wednesday’s session, Taysha Gene Therapies Inc. (NASDAQ:TSHA) marked $2.12 per share, down from $2.20 in the previous session. While Taysha Gene Therapies Inc. has underperformed by -3.64%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TSHA fell by -82.12%, with highs and lows ranging from […]

US Post News | January 5, 2023

These strategies will help Taysha Gene Therapies Inc. (TSHA) succeed

As of Tuesday, Taysha Gene Therapies Inc.’s (NASDAQ:TSHA) stock closed at $1.91, down from $2.08 the previous day. While Taysha Gene Therapies Inc. has underperformed by -8.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TSHA fell by -84.93%, with highs and lows ranging from $13.31 […]

US Post News | December 28, 2022

Have you been able to find a good deal on Taysha Gene Therapies Inc.’s shares?

The share price of Taysha Gene Therapies Inc. (NASDAQ:TSHA) fell to $1.94 per share on Monday from $2.14. While Taysha Gene Therapies Inc. has underperformed by -9.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TSHA fell by -87.08%, with highs and lows ranging from $15.24 […]

US Post News | December 20, 2022

Taysha Gene Therapies names new CEO (NASDAQ:TSHA)

Taysha Gene Therapies'' (TSHA) Chair of the Board of Directors, Sean P

Seeking Alpha | December 19, 2022

Read More 'TSHA' Stories Here

TSHA Price Returns

1-mo -27.43%
3-mo -6.29%
6-mo -61.68%
1-year -79.37%
3-year N/A
5-year N/A
YTD -27.43%
2022 -80.60%
2021 -56.10%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6591 seconds.